Follow Us:Respiratio 2018; 8 (1-2):44-55
PROCJENA KVALITETA ŽIVOTA PACIJENATA OBOLJELIH OD HOBP-a U C I D STADIJUMU BOLESTI U PORODIČNOJ MEDICINI
ASSESSMENT OF THE QUALITY OF LIFE PATIENTS WITH C AND D STADIUM COPD IN FAMILY MEDICINE
Milica Volaš Tovirac¹, Kosana Stanetić², Mirko Stanetić²,Sanja Janković³
¹ JZU Dom zdravlja Doboj , Republika Srpska ,Bosna i Hercegovina
²Univerzitet u Banjoj Luci, Medicinski Fakultet, Banja Luka, Bosna i Hercegovina
³Dom Zdravlja Banja Luka, Banja Luka, Republika Srpska , Bosna i Hercegovina
Original research
Naučni članak
doi: 10.26601/rsp.aprs.18.6
Sažetak: Uvod: Kvalitet života pacijenata oboljelih od HOBP-a opada sa težinom bolesti, a pored pogoršanja stadijuma HOBP-a vjerovatno je povezan i sa velikim brojem komorbiditeta.
Cilj: Ispitati kvalitet života pacijenata u C i D stadijumu bolesti; uticaj pola, životne dobi, pušenja, mjesta stanovanja i ukupnog broja inhalatornih lijekova na kvalitet života pacijenata.
Metode: Istraživanje je opservaciona studija sa ciljem procjene kvaliteta života među pacijentima oboljelim od HOBP-a u C i D stadijumu. Istraživanje je provedeno u JZU Dom zdravlja Banja Lukau periodu od 01.02.-31.12.2017.godine anketiranjem pacijenata uz pomoć upitnika SGRQ (St. George's Respiratory Questionnaire). Ocjena stadijuma bolesti i broja egzacerbacija je vršena na osnovu specijalističkih nalaza i CAT (COPD assessment test) upitnika. Podaci su upoređivani po polu, dobu, pušačkom statusu,mjestu stanovanja i broju inhalatornih lijekova.
Rezultati: Istraživanjem je obuhvaćeno 85 pacijenata, 50.6% muškog i 49.4% ženskog pola. U C stadijumu HOBP prosječna vrijednost kvaliteta života mjerena pomoću SGRQ je bila 41±16, a u D stadijumu 66±15. Dokazano je da postoji visoko statistički značajna razlika u kvalitetu života između ove dve grupe ispitanika (p=,000) u svim segmentima SGRQ. Pacijenti sa manje egzacerbacija imaju statistički značajno bolji kvalitet života u odnosu na pacijente sa više od dvije egzacerbacije u protekloj godini (p=,001). Pacijenti ženskog pola i oni koji žive na selu imaju statistički značajno lošiji kvalitet života, dok pušenje i životno doba ne utiču na kvalitet života ispitanika.
Zaključak: Praćenje kvaliteta života pacijenata sa HOBP-om je neophodno radi adekvatnog liječenja, ali nam može ukazati i na pacijente sa povećanim rizikom od komplikacija. Ovim istraživanjem je pokazano da se posebna pažnja treba posvetiti pacijentima iz ruralnih oblasti i ženama, te da mlađa životna dob nije prediktor boljeg ishoda liječenja. Potrebna je stalna edukacija i monitoring uzimanja inhalatorne terapije kako od strane pulmologa tako i porodičnog ljekara, kao i savjetovanje i motivisanje za prestanak pušenja.
Klučne riječi: hronična opstruktivna bolest pluća, kvalitet života
LITERATURA
|
1. World Health Organisation. Chronic respiratory diseases, Burden of COPD. Avaible from: www.who.int/respiratory/COPD/burden/en/ [Cited 2017 Decembar 6.] |
|
|
|
|
|
2. Pocket Guide to COPD Diagnosis, Managment and Prevetion; 2017 Report. Avaible from: http://goldcopd.org/wp-content/uploads/2016/12/wms-GOLD-2017-Pocket-Guide.pdf [cited 2017 Dec 14] |
|
|
|
|
|
3. Qaseem A, Wilt TJ, Weinberg SE et al. Diagnosis et managment of stable chronic obstructive pulmonary disease: a clinical practice guideline update from American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society.Ann Intern Med 2011;155(3):179-91. |
|
|
|
|
|
4. Mannino DM,Buist AS: Global burden of COPD: risk factors, prevalenece and future trends. Lancet. 2007;370:(9589)765-73. |
|
|
|
|
|
5. Burney P: The pharmacoepidemiology of COPD: resent advences and methodological discussion. EurRespir J 2003;43:15-445. |
|
|
|
|
|
6. Hy J, Chen B, Yin Z, Zia L,Zhou Y, Jin T. Increased risk of chronic obstructive pulmonary diseases in cokeoven workers: interreaction betwean occupational exposure and smoking: Thorax. 2006;61(4):290-5. |
|
|
|
|
|
7. 7. Lozano K, Naghavi M, Foreman K, ET AL. Global and regional mortality from 235 causes of death for 20 age groups in 1990and 2010: a systematic analisis for Global Burden of Disease Study 2010. Lancet 2012; 380 (9859):2095-128. Avible form:https://www.ncbi.nlm.nih.gov/pubmed/23245604 [cited 2018 Jan 28] |
|
|
|
|
|
8. 8.Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002. To 2030. PLOS Med 2006;3(11): e 442. Aviable from: http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.0030442 [cited 2018 Feb 19] |
|
|
|
|
|
9. 9. Stern DA, Morgan WJ, Wright AL, Martinez FD. Poor airway function in early infancy and lung function by age 22 years: a non selective longitudinal cohort study. Lancet 2007;370(9589):758-64. |
|
|
|
|
|
10. 10. De Marco R, Accordini S, Marcon A, Cerveri I, Antó JM, Gislason T. Et al. Risk factors for chronic obstructive pulmonary disease in a European cohort of young adults European Community Respiratory Health Survay (ECRHS) Am J Respir Crit Care Med 2011;183:891-7. |
|
|
|
|
|
11. 11.Liu Y, Plesents RA, Croft JB, Wheaton AG, Heidari K, Malarcher AM et al. Smoking duration, respiratory symptoms, and COPD in adultsaged≥45 years with smoking history.Int J Chon Obstruct Pulmon Dis 2015;10:1409-16. |
|
|
|
|
|
12. 12.Eisner M, Anthonisen N, Coultas D, Kuenzli N, Perez-Padilla R, Postma D et al. An Official American Thoracic Society Public Policy Steatment: Novel risk factors and the Global burden of COPD.American Journal of Respiratory and Critical Care Medicine.2010;182(5):693-718. |
|
|
|
|
|
13. 13.Stoller JK, Aboussauan LS, Alpha 1-antitripsin deficiency. Lancet 2005;365(9478):2225-36. |
|
|
|
|
|
14. 14.Gershon AS, Warner L, Cascagnatte P, Victor JC, To T. Lifetime risk of developing chronic obstructive pulmonary didease: a longitudinal population study: Lancet 2011,378(9795):991-6. |
|
|
|
|
|
15. 15.Silva GE, Sherrill DL, Guerra S, Barbee RA. Asthma as a risk factor for COPD in a longitudinal study. Chest 2004;126(1):59-65. |
|
|
|
|
|
16. 16.Jones PW. Health status measurment in chronic obstructive pulmonary disease. Thorax 2001;56(11):880-7. |
|
|
|
|
|
17. 17.Goossens LM, Leimer I, Metzdorf N, Becker K, Rutten-van M̀̀ӧlken MP. Does the 2013 GOLD classification improve the ability to predict lung function decline, exacerbation and mortality: a post-hoc analisis of the 4-year uplift trial.BMC Pulm Med 2014;14:163. |
|
|
|
|
|
18. 18.Kim J, Yoon HI, Lee CH et al. Lung function decline rates according to GOLD group in patients with chronic obstructive pulmonary disease. Int J Chr Obstr Pulmon Dis. 2015;10:1819-27. |
|
|
|
|
|
19. 19.Wedzicha J, Seemungal T. COPD exacerbations: defining their cause and prevention. Lancet.2007;37:786-96. |
|
|
|
|
|
20. American Thoracic Society St. George's Respiratory Questionnaire (SGRQ) Last Reviewed June 2016. Avaible from: https://www.thoracic.org/members/assemblies/assemblies/srn/questionaires/sgrq.php [Cited 2017 Dec 14] |
|
|
|
|
|
21. Jones PW, Quirk FH, Bareystock CM. A self-complite measure for chronic airflow limitation-the St. George's Respiratory Questionnaire. Am Rev Resir Dis. 1992;145:1321-1327. Avaible from: http://thorax.bmj.com/content/56/11/880.info [cited 2018 Feb 27] |
|
|
|
|
|
22. Jones PW. St. George's Respiratory Questionnaire Manual 2009. Avaible from: http://www.healthstatus.sgul.ac.uk/SGRQ_download/SGRQ%20Manual%20June%202009.pdf [cited 2018 Mart 12] |
|
|
|
|
|
23. Chetta A. Oliveri D: The COPD Assessment Test in the evaluation of chronic obstructive pulmonary disease exacerbations. Expert RevREspMed. 2012,6(4):373-375. Medscape Avaible from: http://www.medscape.com/viewarticle/771132 [Cited 2017 Dec 14] |
|
|
|
|
|
24. Han MLK,Make B, Muellerova H et al. Implications of GOLD 2011 Disease Severity Clasification in the COPDGene Cohort, Lancet Respir Med 2013;1(1):43-50. Avaible from:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4105297/?report=reader [Cited 2018 Mart 3] |
|
|
|
|
|
25. Kim S, Oh J, Lim SC. Differences in classification of COPD group using COPD assessment test (CAT) or modifid Medical Research Counsil (mMRC) dyspnea scores: a cross-sectional analisis.BMJ Pulm Med.2013;13:35 Avaible from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3680333/#!po=88.4615 [Cited 2018 Mart 3] |
|
|
|
|
|
26. Mapel DW, Dalala AA, Johnson PT, Becker LK, Hunter AG. Application of the new GOLD COPD staging system to a US primary care cohort, with compersion to physicians and patient impressions of severity. Int J Chron Obstruct Pulmon Dis 2015; 10:1477-86. Avaible from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4524525/#!po=2.27273 [Cited 2018 Mart 3] |
|
|
|
|
|
27. Gvozdenović B, Mihailović Vučinić V, VukovićM, Gvozdenović A, Dudvarski Ilić A, Stjepanović IM. Prediktori pogoršanja simptoma i kvaliteta života bolesnika sa sarkoidozom, Med Pregl. 2013;66(1):77-83. |
|
|
|
|
|
28. Tariq SM, Thomas EC. Maintenance therapy in COPD: Time to phase out ICS and switch to the new LAMA/LABA inhalers? Int J Chron Obstruct Pulmon Dis.2017;12:1877-82. |
|
|
|
|
|
29. Self TH, Ellingson S. New treatment option for chronic obstructive pulmonary disease: two long-acting bronchodilataors in a single metred-dose inhaler. Am J Med 2017;130(1):1251-4. |
|
|
|
|
|
30. Stanetić K, Račić M, Petrović V, Jatić Z, Savić S, Kusmuk S. Prevencija najčešćih hroničnih bolesti. Narodna i univerzitetska biblioteka Republike Srpske; Banja Luka 2017. |
|
|
|
|
|
31. Ospina MB, Michas M, Deuchar L, Leigh R, Dubios R. Et al. Development of patient-centred, evidence-based and consensus based discharge care bundle for patients with acute exacerbation of chronic obstructive pulmonary disease. BMJ Open Respir Rec.2018; 5(1): e000265 |
|
|
|
|
|
32. Criner GJ; Bourbean J, Stickland MK et al. Prevention of acute exacerbations of COPD. Chest 2015;147(4):894-942. |
|
|
|
|
|
33. Martin AL, Marvel J, Fahrbach K, Cadarette SM, Wilcox TK, Donohue JF. The association of lung function and St. George's respiratory questionnaire with exacerbations in COPD: a systemic literature review and regression analysis. Respir Rec. 2016;17:40. |
|
|
|
|
|
34. Ferrer M, Vilasante C, Alonso J. Et al. Interpretation of quality of life scores from the St. George's respiratory questionnaire. Eur Respir J 2002;19:405-13. |
|
|
|
|
|
35. Lee H, Jhun BW, Cho J, Yoo KH, Lee JH, Kim DK, et al. Different impacts of respiratory symptoms and comorbidites on COPD-specific health-related quality of life by COPD severity. Int J Chron Obstruct Pulmon Dis.2017;12:3301-10. |
|
|
|
|
|
36. Torres JP, Casanova C, Hernàndez C, Abreu J, Montejo de Garcini A, Aquirre-Jaime A, Celli BR. Gender associated differences in determinants of quality of life in patients with COPD: a case series study. Health Qual. Life Outcomes 2006;4:72. |
|
|
|
|
|
37. Torres JP, Casanova C, Hernàndez C, Abreu J, Aquirre-Jaime A, Celli BR. Gender and COPD in patienets attending a pulmonary clinic. Chest 2005;128(4):2012-6. |
|
|
|
|
|
38. Croft JB, Wheaton AG, Lin Y, Xu F, Lu H, Matthews KA, Cunningham TJ, Wang Y, Holt JB. Urban-Rural Country and State differences in chronic obstructive pulmonary disease- United States 2015. MMWR Morb Mortal Wkly Rep. 2018;67(7):205-211. |
|
|
|
|
|
39. Sana A, Somda SMA, Meda N, Bouland C. Chronic obstructive pulmonary disease associated with biomass fuel use in women: a systematic review and meta-analisis. BMJ Open Respir Rec 2018;5(1):e000246. |
|
|
|
|
|
40. Yan R, Wang Y, Bo J, Li W. Healthy lifestyle behaviors among individuals with chronic obstructive pulmonary disease in urban and rural communities in China: a large community-based epidemiological stady.Int J Chron Obstruct Pulm Dis. 2017;12:3311-21. |
|
|
|
|
|
41. Chen J, Chen Y, Chen P, Lui Z, Luo H, Cai S. Effectivnes of individual counseling for smoking cessation in smokers with chronic obstructive pulmonary disease and asymptomatic smokers. Exp Ther Med 2014;7(3):716-20. |
|
|
|
|
|
42. Putha N, Barr RG, Han Mk, Woodruff PG, Bleecker ER, Kanner RE, Martinez FJ et al. Understanding the impact of second-hand smoke exposure on clinical outcomes in participans with COPD in the SPIROMICS cohort. Torax 2016: thoraxjnl-2015-207487. |
|
Milica Volaš Tovirac
Adress:Lipac 86,74 000 Doboj
Phone:+38765056813
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.